Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.O)

IRWD.O on Nasdaq

15.60USD
12:04pm EDT
Change (% chg)

$0.18 (+1.17%)
Prev Close
$15.42
Open
$15.43
Day's High
$15.62
Day's Low
$15.29
Volume
283,119
Avg. Vol
1,172,187
52-wk High
$19.94
52-wk Low
$12.48

Latest Key Developments (Source: Significant Developments)

Ironwood Pharma says CFO Tom Graney will leave company
Wednesday, 6 Sep 2017 08:00am EDT 

Sept 6 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company.Ironwood Pharmaceuticals Inc - ‍gina Consylman will serve as company's interim chief financial officer​.Ironwood Pharmaceuticals Inc - ‍initiated search for a senior business strategy and finance executive to complement its current leadership team​.  Full Article

Ironwood Pharma announces FDA approval of Duzallo to treat hyperuricemia in patients with uncontrolled gout
Monday, 21 Aug 2017 08:00am EDT 

Aug 21 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals announces FDA approval of Duzallo (Lesinurad And Allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout.Ironwood Pharmaceuticals inc- ‍Ironwood expects Duzallo to be commercially available early in Q4 of 2017​.  Full Article

Ironwood Pharmaceuticals Q2 loss per share $0.30
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals provides second quarter 2017 investor update.Q2 non-GAAP loss per share $0.28.Q2 loss per share $0.30.Q2 revenue $65.1 million versus I/B/E/S view $70.8 million.Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Ironwood Pharmaceuticals - sees ‍combined Allergan, Ironwood total 2017 marketing and sales expenses for Linzess to be in range of $250 million to $280 million​.  Full Article

Ironwood Pharmaceuticals reports Q1 loss per share of $0.36
Monday, 8 May 2017 08:00am EDT 

May 8 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood pharmaceuticals provides first quarter 2017 investor update.Q1 non-gaap loss per share $0.33.Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Q1 loss per share $0.36.Q1 revenue $52.2 million.Q1 revenue view $69.7 million -- Thomson Reuters I/B/E/S.  Full Article

Ironwood pharmaceuticals qtrly loss per share $0.09
Tuesday, 21 Feb 2017 04:01pm EST 

Ironwood Pharmaceuticals Inc : Qtrly loss per share $0.09 . Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million. . Qtrly non-gaap loss per share $0.12 . Ironwood Pharmaceuticals Inc - expects combined allergan and ironwood total 2017 marketing and sales expenses for linzess to be in range of $250 million to $280 million . Q4 earnings per share view $-0.24, revenue view $76.9 million -- Thomson Reuters I/B/E/S .Expects to use less than $100 million in cash for operations in 2017.  Full Article

Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan
Sunday, 29 Jan 2017 07:00pm EST 

Astellas Pharma Inc <4503.T>: Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan . Says Linaclotide is approved in Japan as first prescription treatment for adults with irritable bowel syndrome with constipation . Says patients in phase III cc trial in Japan continue to receive open-label Linaclotide for an additional 52 weeks . Astellas Pharma -top-line trial results indicate that linaclotide-treated patients showed statistically significant improvement compared to placebo-treated patients .Says most common adverse event reported in this trial was diarrhea.  Full Article

U.S. FDA approves 72 mcg dose of linzess® (linaclotide) for adults with chronic idiopathic constipation
Thursday, 26 Jan 2017 07:01am EST 

Allergan Plc : Says new dose is expected to be available in q1 of 2017 .U.S. Food and Drug Administration approves 72 mcg dose of linzess® (linaclotide) for adults with chronic idiopathic constipation.  Full Article

Ironwood Pharma Q2 adj shr loss $0.16
Thursday, 4 Aug 2016 04:25pm EDT 

Ironwood Pharmaceuticals Inc : Ironwood pharmaceuticals provides second quarter 2016 investor update . Q2 gaap loss per share $0.15 . Q2 revenue $54.4 million versus i/b/e/s view $55.5 million . Q2 non-gaap loss per share $0.16 . Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S . Allergan and ironwood continue to expect total 2016 marketing and sales expenses for linzess to be in range of $230 million to $260 million . Says continues to expect to use less than $70 million in cash for operations in 2016 . Q2 earnings per share view $-0.15, revenue view $55.5 million -- Thomson Reuters I/B/E/S Further company coverage: [IRWD.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Allergan says supplemental NDA for 72 mcg Linaclotide accepted for FDA review
Thursday, 9 Jun 2016 08:01am EDT 

Allergan Plc : FDA prescription drug user fee act (PDUFA) target action date is expected to occur in early 2017 . FDA accepted for review SNDA for 72 mcg dose of Linaclotide for use in treatment of adults with chronic idiopathic constipation .Ironwood and Allergan announce supplemental new drug application for 72 mcg Linaclotide in chronic idiopathic constipation has been accepted for FDA review.  Full Article

Ironwood Pharmaceuticals Q1 gaap loss per share $0.09
Monday, 9 May 2016 04:05pm EDT 

Ironwood Pharmaceuticals Inc : Ironwood on track to achieve positive cash flow in 2018 . Ironwood pharmaceuticals provides first quarter 2016 investor update . Q1 non-gaap loss per share $0.08 . Q1 gaap loss per share $0.09 . Q1 revenue $66 million versus i/b/e/s view $53.6 million .Q1 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Ironwood Pharma says CFO Tom Graney will leave company

* Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company